chronic obesity

By Targets:	Cannabinoid Receptor (1) Endogenous Metabolite (1) ERK (1) Free Fatty Acid Receptor (1) GnRH Receptor (1) Melanocortin Receptor (3) Monoamine Oxidase (2) NO Synthase (1)
By Research Areas:	Cardiovascular Disease (2) Inflammation/Immunology (7) Metabolic Disease (8)

Targets Recommended: Fat Mass and Obesity-associated Protein (FTO)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-147301A

Resomelagon acetate AP1189 acetate	Melanocortin Receptor	Metabolic Disease Inflammation/Immunology
Resomelagon (AP1189) acetate is a potent, orally active melanocortin receptor (MR) agonist about MC₁ and MC₃. Resomelagon acetate induces ERK1/2 phosphorylation and Ca ²⁺ mobilization. Resomelagon acetate has anti-inflammatory activity. Resomelagon acetate can be used for obesity and chronic inflammation research .

HY-147301

Resomelagon AP1189	Melanocortin Receptor	Metabolic Disease Inflammation/Immunology
Resomelagon (AP1189) is a potent, orally active melanocortin receptor (MR) agonist about MC₁ and MC₃. Resomelagon induces ERK1/2 phosphorylation and Ca ²⁺ mobilization. Resomelagon has anti-inflammatory activity. Resomelagon can be used for obesity and chronic inflammation research .

HY-113334

Turanose	Endogenous Metabolite	Metabolic Disease Inflammation/Immunology
Turanose is an isomer of Sucrose that naturally exists in honey. Turanose has anti-inflammatory and regulates adipogenesis effect. Turanose has potential for obesity and related chronic diseases research .

HY-141411A

Zevaquenabant (S)-MRI-1867	Cannabinoid Receptor NO Synthase	Metabolic Disease
Zevaquenabant ((S)-MRI-1867) is a peripherally restricted, orally bioavailable dual cannabinoid CB1 receptor and inducible NOS antagonist. Zevaquenabant ameliorates obesity-induced chronic kidney disease (CKD) .

HY-P10378

GPR10 agonist 1	GnRH Receptor	Metabolic Disease
GPR10 agonist 1 (compound 18-S4) is a potent GPR10 agonist with EC₅₀ values of 80, 7.8 nM in the presence (10%) or absence (0%) of FBS, respectively. GPR10 agonist 1 has the potential for the research of chronic obesity .

HY-147301B

Resomelagon methanesulfonate AP1189 methanesulfonate	Melanocortin Receptor ERK	Inflammation/Immunology
Resomelagon methanesulfonate (AP1189 methanesulfonate) is the methanesulfonate salt form of Resomelagon (HY-147301). Resomelagon methanesulfonate is an orally active melanocortin receptor (MR) agonist. Resomelagon methanesulfonate induces ERK1/2 phosphorylation and Ca ²⁺ mobilization. Resomelagon methanesulfonate exhibits anti-inflammatory activity in mouse peritonitis and peritonitis model. Resomelagon methanesulfonate can be used for obesity and chronic inflammation research .

HY-143721

SSAO inhibitor-2	Monoamine Oxidase	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
SSAO inhibitor-2 (Compound 1) is a semicarbazide-sensitive amine oxidase (SSAO) inhibitor with IC₅₀s of <10 nM, and 10-100 μM for human SSAO and MAO-A, respectively. SSAO inhibitor-3 can be used for the research of atherosclerosis, diabetes and its complications, obesity, stroke, chronic kidney disease, retinopathy, chronic obstructive pulmonary disease (COPD), autoimmune diseases, multiple sclerosis, etc .

HY-143723

SSAO inhibitor-3	Monoamine Oxidase	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
SSAO inhibitor-3 (Compound 2) is a semicarbazide-sensitive amine oxidase (SSAO) inhibitor with IC₅₀s of <10 nM, and 0.1-10 μM for human SSAO and AOC1, respectively. SSAO inhibitor-3 can be used for the research of atherosclerosis, diabetes and its complications, obesity, stroke, chronic kidney disease, retinopathy, chronic obstructive pulmonary disease (COPD), autoimmune diseases, multiple sclerosis, etc .

HY-109692

GPR120 Agonist 5	Free Fatty Acid Receptor	Metabolic Disease Inflammation/Immunology
GPR120 Agonist 5 (compound 12) is an agonist targeting GPR120 (EC₅₀=1.2 μM). GPR120 Agonist 5 promotes the release of glucagon-like 1 (GLP-1) by binding to the GPR120 receptor, which in turn binds to its receptors on pancreatic beta cells, increasing insulin secretion and thereby lowering blood sugar levels. GPR120 Agonist 5 also helps reduce chronic low-grade inflammation, which plays an important role in the pathogenesis of obesity, insulin resistance, and type 2 diabetes. GPR120 Agonist 5 can be used to investigate the mechanism of action of GPR120 in metabolic and inflammatory diseases .

Cat. No.	Product Name

HY-L087

Anti-Obesity Compound Library	2,735 compounds
Obesity is widely recognized as the largest and fastest growing public health problem and is associated with numerous chronic disorders including osteoarthritis, obstructive sleep apnea, gallstones, fatty liver disease, reproductive and gastrointestinal cancers, dyslipidemia, hypertension, type 2 diabetes, heart failure, coronary artery disease, stroke, etc. Although obesity has long been associated with serious health issues, it has only recently been regarded as a disease in the sense of being a specific target for medical therapy. Obesity may be viewed as the dysregulation of two physiological functions, appetite regulation and energy metabolism, which combine to create disordered energy balance. Consequently, developing obesity treatments that target novel pathways is a growing focus for both biopharmaceutical industries. MCE Anti-Obesity Compound Library owns a unique collection of 2,735 compounds, which mainly target signaling pathway of controlling appetite, fatty acid metabolism and energy expenditure, etc. This library is a useful tool for discovery anti-obesity drugs.

Anti-Obesity Compound Library

2,735 compounds

Obesity is widely recognized as the largest and fastest growing public health problem and is associated with numerous chronic disorders including osteoarthritis, obstructive sleep apnea, gallstones, fatty liver disease, reproductive and gastrointestinal cancers, dyslipidemia, hypertension, type 2 diabetes, heart failure, coronary artery disease, stroke, etc. Although obesity has long been associated with serious health issues, it has only recently been regarded as a disease in the sense of being a specific target for medical therapy. Obesity may be viewed as the dysregulation of two physiological functions, appetite regulation and energy metabolism, which combine to create disordered energy balance. Consequently, developing obesity treatments that target novel pathways is a growing focus for both biopharmaceutical industries.

MCE Anti-Obesity Compound Library owns a unique collection of 2,735 compounds, which mainly target signaling pathway of controlling appetite, fatty acid metabolism and energy expenditure, etc. This library is a useful tool for discovery anti-obesity drugs.

Cat. No.	Product Name	Target	Research Area

HY-P10378

GPR10 agonist 1	GnRH Receptor	Metabolic Disease
GPR10 agonist 1 (compound 18-S4) is a potent GPR10 agonist with EC₅₀ values of 80, 7.8 nM in the presence (10%) or absence (0%) of FBS, respectively. GPR10 agonist 1 has the potential for the research of chronic obesity .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-113334

Turanose	Structural Classification Microorganisms Animals Classification of Application Fields Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields Saccharides	Endogenous Metabolite
Turanose is an isomer of Sucrose that naturally exists in honey. Turanose has anti-inflammatory and regulates adipogenesis effect. Turanose has potential for obesity and related chronic diseases research .

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products